[Facial rejuvenation using L-polylactic acid: about 298 successive cases].
OBJECTIVE
Patients seeking care of facial ageing demand an aesthetic result that appears natural and is very safe, with techniques the less invasive possible. Our series of cases helps analyse the efficiency and safety of L-polylactic acid in the management of facial ageing.


METHODS
Retrospective analysis of a single series of patients treated with L-polylactic acid (Sculptra™) between September 2000 and September 2007. All patients over 18 years, consulting for facial ageing and/or loss of volume and treated with L-polylactic acid injections, were included in our evaluation. Patients with facial lipoatrophy related to HIV were excluded from this evaluation.


RESULTS
The series consist of 298 patients who received a total of 582 injections of L-polylactic acid. The reason for consultation was basically facial ageing (85.9%) and loss of facial volume (12.1%). Ninety-one percent patients were satisfied with the correcting effect. Fourteen patients (4.7%) showed a late adverse event: palpable but non-visible subcutaneous indurations (11 patients, 3.7%) and deep, little visible, multiple granuloma-like nodules that required treatment (three patients, 1%).


CONCLUSIONS
L-polylactic acid is a filler that facilitates natural correction of ageing with minimum adverse event. Its mechanism of action gives it a special place among other injectable materials. The surgeon who conducts adipocyte grafting will appreciate its ease of use and remodelling volumising effect.
Chirurgie plastique, 14, avenue Kleber, 75116 Paris, France. fmasveyraud@club-internet.fr
F
F
Olivier Masveyraud
D000328:Adult; D000368:Aged; D002482:Cellulose / Q000008:administration & dosage* / Q000009:adverse effects; D003357:Cosmetic Techniques / Q000009:adverse effects; D004954:Esthetics; D005145:Face; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D019344:Lactic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008353:Mannitol / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D017060:Patient Satisfaction; D012060:Rejuvenation; D019233:Retreatment; D012189:Retrospective Studies; D015595:Skin Aging / Q000187:drug effects*
C482305:New-Fill; D019344:Lactic Acid; D008353:Mannitol; D002482:Cellulose